Janssen Announces U.S. FDA Approval of TREMFYA™ (Guselkumab) for the Treatment
Mayo

Janssen Announces U.S. FDA Approval of TREMFYA™ (Guselkumab) for the Treatment

2020 × 2700 px October 12, 2024 Zeus

Janssen Announces U.S. FDA Approval of TREMFYA™ (Guselkumab) for the Treatment is a high-quality image in the Mayo collection, available at 2020 × 2700 pixels resolution — ideal for both digital and print use.

Learn what Tremfya is used for in treating plaque psoriasis and psoriatic arthritis. Discover how this biologic medication works to manage your symptoms.

Image Details

TitleJanssen Announces U.S. FDA Approval of TREMFYA™ (Guselkumab) for the Treatment
Dimensions2020 × 2700 px
CategoryMayo
PublishedOctober 12, 2024
AuthorZeus
Downloads2,479
Views159

Frequently Asked Questions

This image has a resolution of 2020 × 2700 pixels. It is suitable for high-quality printing, digital presentations, and web use without losing clarity.
This image is part of the Mayo collection. You can browse more images in this category to find similar content.
Click the Download button above the image to save it directly to your device. The image is provided in its original resolution of 2020 × 2700 px.
Yes! Scroll down to the More Images section below to explore related Mayo images. You can also visit the full article for more context and a complete image gallery.

Read full article: What Is Tremfya Used For